# PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

> **NCT05772273** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 43 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Donor lymphocyte infusion
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05772273
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05772273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05772273, "PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT05772273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*